💪 Immunotherapy Power Duo: Nivolumab + Ipilimumab vs. TKIs in HCC
Dr RR Baliga's "Got Knowledge Doc" Podkast
May 16, 20254m 17s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
🚀 New Breakthrough in Liver Cancer! 🌟
The CheckMate 9DW trial shows that Nivolumab + Ipilimumab significantly improves survival in unresectable #HCC compared to lenvatinib/sorafenib! 🧬💪
#Immunotherapy #CancerResearch #LiverCancer #Oncology 💉